Hainan Shuangcheng Files Paragraph IV Patent Declaration for Paclitaxel, Albumin-Bound
China’s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHE: 002693) has announced a Paragraph IV patent declaration...
Cancer
Immunotech Biopharm’s CAR-T-19-D2 IND Filing Accepted by NMPA
China-based chimeric antigen receptor T-cell (CAR-T) specialist Immunotech Biopharm Ltd (HKG: 6978) has announced that...
Guangzhou Mygene Raises ‘Hundreds of Millions’ in Series C Financing Led by Efund Capital
China-based molecular diagnostic product developer Guangzhou Mygene Medical Technology Co., Ltd reportedly raised “hundreds of...
Carrier Biomed Raises ‘Tens of Millions’ in Series A+ Financing Round
Carrier Biomed (Soohow) Co., Ltd, an exosome technology developer based in Suzhou, has reportedly raised...
InnoCare Pharma Receives Hong Kong Approval for Tafasitamab in DLBCL
China-based biopharma InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving market approval from the...
CStone Pharmaceuticals Publishes Ayvakit Study Results on Oncologist Website
China-based CStone Pharmaceuticals (HKG: 2616) has published the results of the China-based bridging NAVIGATOR study...
Biosion Completes Series B Financing Round Led by Guangfa Xinde Investment
Biosion, a global, clinical-stage biotech committed to developing antibody-based therapies targeting immune and oncologic diseases,...
Ablaze Pharma and Yonghe Partner for Targeted Radiotherapy Development
China-based Ablaze Pharma and Yonghe Pharmaceutical have struck a partnership agreement for the research and...
Innovent Biologics’ GFH925 Receives Breakthrough Therapy Designation
China’s Center for Drug Evaluation (CDE) website indicates that China-based Innovent Biologics (HKG: 1801) has...
Junshi Biosciences’ PD-1 Inhibitor Tuoyi Faces FDA Review Delay
Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that they have not received...
Antengene and MSD Collaborate on Global Clinical Study for ATG-037
China-based Antengene Corporation Limited (HKG: 6996) has announced a global clinical collaboration with Merck, Sharp...
IASO Biotherapeutics Receives FDA Approval for CT103A IND Application
China-based IASO Biotherapeutics has announced approval from the US FDA for an Investigational New Drug...
CSPC’s NBL-020 Receives FDA IND Approval for Advanced Solid Tumors
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving Investigational New Drug (IND) approval...
Jiangsu Chia Tai Tianqing’s TQB2102m Gains NMPA Clinical Approval
Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd’s (CTTQ) Category 1 biologic product TQB2102m, an HER2...
Jing Medicine’s HJM-353 Gains Clinical Trial Approvals in US and China
China-based Jing Medicine Technology (Shanghai) Co., Ltd’s HJM-353 has obtained clinical trial approvals in the...
Junshi Biosciences Licenses PD-1 Inhibitor Tuoyi to Hikma MENA FZE
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced a licensing agreement with UK-headquartered Hikma...
MSD and Kelun Biotech Ink Record-Breaking ADC Deal
Merck, Sharp & Dohme (MSD, NYSE: MRK) has set a new benchmark for the largest...
Shyndec’s Generic Cytosar-U Gains Marketing Approval in China
China-based Shanghai Shyndec Pharmaceutical Co., Ltd (SHA: 600420) has announced that its generic version of...
Antengene Files for Xpovio Approval in Macau, Malaysia, and Thailand
Antengene Corp., Ltd (HKG: 6996) has announced market filings for its Xpovio (selinexor) in Macau,...
Innovent Biologics Announces Strategic Partnerships to Form Tumor Diagnosis and Treatment Alliance
China-based Innovent Biologics (HKG: 1801) has announced a series of strategic partnerships with compatriot firms...